Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
L-карнитин в медицинской практике: доказанные эффекты
А.Л.Верткин. L-карнитин в медицинской практике: доказанные эффекты. Consilium Medicum. Неврология (Прил.). 2012; 1: 83-86.
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Полный текст
Список литературы
1. Бодыхов М.К., Стаховская Л.В., Салимов К.А., СунЧер И. Оценка безопасности и эффективности препарата «Элькар» (левокарнитин) у пациентов в остром периоде ишемического инсульта в каротидной системе. РМЖ. Неврология. Психиатрия. 2011; 9: 588–90.
2. Гусев Е.И., Скворцова В.И. Нейропротективная терапия ишемического инсульта. Атмосфера. 2002; 1: 3–7.
3. Копелевич В.М. Чудо карнитина. М.: Генезис, 2003.
4. Кузин В.М. Карнитина хлорид (25 лет в клинической практике). РМЖ. 2003; 11 (10): 5–9.
5. Попова Т.Е. Особенности развития и коррекции гипоксии у больных с ишемическим инсультом. Дис. … канд. мед. наук. М, 2001.
6. Семиголовский Н.Ю., Верцинский Е.К., Азанов Б.А. Первый клинический опыт применения инфузионного отечественного препарата левокарнитина при синдроме малого выброса у больных инфарктом миокарда, тромбоэмболией легочной артерии и дилатационной кардиомииопатией. Эфферентная терапия. 2011; 17 (3): 136–7.
7. Adams KE, Cohen MH, Eisenberg D et al. Ethical consideration of complementary and alternative medical therapies in conventional settings. Ann Intern Med 2002; 137: 660–4.
8. Basile A, Jones E. Ammonia and GABA-ergic neurotransmission: interrelated factors in the pathogenesis of hepaticen cephalopathy. Hepatology 1997; 25: 1303–5.
9. Blei A. Brain oedema and portal-systemic encephalopathy. Liver Transpl 2000; 6: S14–20.
10. Evans AM, Fornasini G. Pharmacokinetics of L-carnitine. Clin Pharmacokinet 2003; 42: 941–67.
11. Ferrari R, Merli E, Cicchitelli G et al. Therapeuticeffects of L-carnitine and propionyl-L-carnitine on cardiovascular diseases: a review. Ann N Y Acad Sci 2004; 1033: 79–91.
12. Furchgott RF, Zawadzki JV. Theobligatoryrole of endothelial cell sintherelaxation of arterial smooth muscle by acetylcholine. Nature 1980; 288 (5789): 373–6.
13. Gusev E, Skvortsova V. BrainIschemia. NewYork-Boston-Dordecht-London: Kluwer Academic/Plenum Publishers, 2003; 382.
14. Iliceto S, Scrutinio D, Bruzzi P et al. Effects of L-carnitine administration on left ventricular remodeling after acute anterior myocardial infarction: the L-сarnitine ecocardiografia digital izzatainfarto miocardico (CEDIM) Trial. JACC 1995; 26 (2): 380–7.
15. Jallon P, Picard F. Body weight gainandanti convulsants: a comparative review. Drug Saf 2001; 24 (13): 969–78.
16. Jiménez-Jiménez F, Rubio J, Molina J. Cerebrospinal fluid carnitine levels in patients with Parkinson's disease. J Neurol Sci 1997; 145 (2): 183–5.
17. Lerman A, Burnett JC, Higano ST et al. Long-term L-arginine supple mentation improves small-vessel coronary endothelial function in humans. Circulation 1998; 97: 2123–8.
18. Lockwood A, Yap E, Wong W. Cerebral ammonia metabolism in patients with severe liver disease and minimal hepatic encephalopathy. J Cereb Blood Flow Metab 1991; 11: 337–41.
19. Loster H, Miehe K, Punzel M et al. Prolongedoral L-carnitine substitution increases bicycleergometer performance in patients with severe, ischemical lyinduced cardiacin sufficiency. Cardiovascular Drugsand Therapy 1999; 13: 537–46.
20. Matsuoka M, Igisu H, Kohriyama K, Inoue N. Suppression of neurotoxicity of ammoniaby L-carnitine. Brain Res 1991; 567: 328–31.
21. Meyburg J, Schulze A, Kohlmueller D et al. Postnatal changes in neonatal acylcarnitine profile. Pediatr Res 2001; 49: 125–9.
22. Montgomery S, Thal L, Amrein R. Meta-analysis of double blind randomized controlled clinical trials of acetyl-L-carnitine versus placebo in thetreatment of mildcognitive impairment and mild Alzheimer's disease. Int Clin Psychopharmacol 2003; 18 (2): 61–71.
23. Moretti S, Ruggeri RM, Russo A et al. Usefulness of L-carnitine, a naturally occurring peripheral antagonist of thyroid hormoneaction, iniatrogenic hyperthyroidism: randomized, double – blind, placebo – controlled clinical trial. J Clin Endocrinol Metab 2001; 86: 3579–94.
24. Nałecz K, Miecz D, Berezowski V, Cecchelli R. et al. Carnitine: transport and physiological function sinthebrain. Mol Aspects Med 2004; 25 (5–6): 551–67.
25. Pittler M, Ernst E. Complementary therapies for neuropathic and neuralgic pain: systematic review. Clin J Pain 2008; 24 (8): 731–3.
26. Rebouche CJ. Kinetics, pharmacokinetics, andregulation of L-carnitine and acetyl-L-carnitine metabolism. Ann N Y Acad Sci 2004; 1033: 30–41.
27. Sugimoto T, Araki A, Nishida N et al. Hepatotoxicityinrat following administration of valproicacid: effect of L-carnitine supple mentation. Epilepsia 1987; 28: 373–7.
28. Silva-Adaya D, Pérez-DeLaCruz V, Herrera-Mundo M et al. Excitotoxic damage, disrupted energy metabolism, and oxidative stress in the rat brain: antioxidant and neuroprotectiv eeffects of L-carnitine. J Neurochem 2008; 105 (3): 677–89.
29. Svoboda Z, Kvĕtina J, Herink J et al. Galantamine antiacetyl choline sterase activity inratbrain influenced by L-carnitine. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2005; 149 (2): 335–7.
30. Tarantini G, Scrutinio D, Bruzzi P et al. Метаболическая терапия L-карнитином при переднем остром инфаркте миокарда с подъемом сегмента ST: рандоминизированное клиническое исследование. Рос. кардиол. журн. 2011; 4: 77–84.
31. Therrien G, Rose C, Butterworth J, Butterworth R. Protectiveeffect of L-carnitine in ammonia-precipitated encephalopathy in the portacaval shuntedrat. Hepatology 1997; 25: 551–6.
32. Virmani A, Gaetani F, Imam S et al. Theprotective role of L-carnitine against neurotoxicity evoked by drug of abuse, methamphetamine, could berelated tomitochondrial dysfunction. Ann N Y Acad Sci 2002; 965: 225–32.
2. Гусев Е.И., Скворцова В.И. Нейропротективная терапия ишемического инсульта. Атмосфера. 2002; 1: 3–7.
3. Копелевич В.М. Чудо карнитина. М.: Генезис, 2003.
4. Кузин В.М. Карнитина хлорид (25 лет в клинической практике). РМЖ. 2003; 11 (10): 5–9.
5. Попова Т.Е. Особенности развития и коррекции гипоксии у больных с ишемическим инсультом. Дис. … канд. мед. наук. М, 2001.
6. Семиголовский Н.Ю., Верцинский Е.К., Азанов Б.А. Первый клинический опыт применения инфузионного отечественного препарата левокарнитина при синдроме малого выброса у больных инфарктом миокарда, тромбоэмболией легочной артерии и дилатационной кардиомииопатией. Эфферентная терапия. 2011; 17 (3): 136–7.
7. Adams KE, Cohen MH, Eisenberg D et al. Ethical consideration of complementary and alternative medical therapies in conventional settings. Ann Intern Med 2002; 137: 660–4.
8. Basile A, Jones E. Ammonia and GABA-ergic neurotransmission: interrelated factors in the pathogenesis of hepaticen cephalopathy. Hepatology 1997; 25: 1303–5.
9. Blei A. Brain oedema and portal-systemic encephalopathy. Liver Transpl 2000; 6: S14–20.
10. Evans AM, Fornasini G. Pharmacokinetics of L-carnitine. Clin Pharmacokinet 2003; 42: 941–67.
11. Ferrari R, Merli E, Cicchitelli G et al. Therapeuticeffects of L-carnitine and propionyl-L-carnitine on cardiovascular diseases: a review. Ann N Y Acad Sci 2004; 1033: 79–91.
12. Furchgott RF, Zawadzki JV. Theobligatoryrole of endothelial cell sintherelaxation of arterial smooth muscle by acetylcholine. Nature 1980; 288 (5789): 373–6.
13. Gusev E, Skvortsova V. BrainIschemia. NewYork-Boston-Dordecht-London: Kluwer Academic/Plenum Publishers, 2003; 382.
14. Iliceto S, Scrutinio D, Bruzzi P et al. Effects of L-carnitine administration on left ventricular remodeling after acute anterior myocardial infarction: the L-сarnitine ecocardiografia digital izzatainfarto miocardico (CEDIM) Trial. JACC 1995; 26 (2): 380–7.
15. Jallon P, Picard F. Body weight gainandanti convulsants: a comparative review. Drug Saf 2001; 24 (13): 969–78.
16. Jiménez-Jiménez F, Rubio J, Molina J. Cerebrospinal fluid carnitine levels in patients with Parkinson's disease. J Neurol Sci 1997; 145 (2): 183–5.
17. Lerman A, Burnett JC, Higano ST et al. Long-term L-arginine supple mentation improves small-vessel coronary endothelial function in humans. Circulation 1998; 97: 2123–8.
18. Lockwood A, Yap E, Wong W. Cerebral ammonia metabolism in patients with severe liver disease and minimal hepatic encephalopathy. J Cereb Blood Flow Metab 1991; 11: 337–41.
19. Loster H, Miehe K, Punzel M et al. Prolongedoral L-carnitine substitution increases bicycleergometer performance in patients with severe, ischemical lyinduced cardiacin sufficiency. Cardiovascular Drugsand Therapy 1999; 13: 537–46.
20. Matsuoka M, Igisu H, Kohriyama K, Inoue N. Suppression of neurotoxicity of ammoniaby L-carnitine. Brain Res 1991; 567: 328–31.
21. Meyburg J, Schulze A, Kohlmueller D et al. Postnatal changes in neonatal acylcarnitine profile. Pediatr Res 2001; 49: 125–9.
22. Montgomery S, Thal L, Amrein R. Meta-analysis of double blind randomized controlled clinical trials of acetyl-L-carnitine versus placebo in thetreatment of mildcognitive impairment and mild Alzheimer's disease. Int Clin Psychopharmacol 2003; 18 (2): 61–71.
23. Moretti S, Ruggeri RM, Russo A et al. Usefulness of L-carnitine, a naturally occurring peripheral antagonist of thyroid hormoneaction, iniatrogenic hyperthyroidism: randomized, double – blind, placebo – controlled clinical trial. J Clin Endocrinol Metab 2001; 86: 3579–94.
24. Nałecz K, Miecz D, Berezowski V, Cecchelli R. et al. Carnitine: transport and physiological function sinthebrain. Mol Aspects Med 2004; 25 (5–6): 551–67.
25. Pittler M, Ernst E. Complementary therapies for neuropathic and neuralgic pain: systematic review. Clin J Pain 2008; 24 (8): 731–3.
26. Rebouche CJ. Kinetics, pharmacokinetics, andregulation of L-carnitine and acetyl-L-carnitine metabolism. Ann N Y Acad Sci 2004; 1033: 30–41.
27. Sugimoto T, Araki A, Nishida N et al. Hepatotoxicityinrat following administration of valproicacid: effect of L-carnitine supple mentation. Epilepsia 1987; 28: 373–7.
28. Silva-Adaya D, Pérez-DeLaCruz V, Herrera-Mundo M et al. Excitotoxic damage, disrupted energy metabolism, and oxidative stress in the rat brain: antioxidant and neuroprotectiv eeffects of L-carnitine. J Neurochem 2008; 105 (3): 677–89.
29. Svoboda Z, Kvĕtina J, Herink J et al. Galantamine antiacetyl choline sterase activity inratbrain influenced by L-carnitine. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2005; 149 (2): 335–7.
30. Tarantini G, Scrutinio D, Bruzzi P et al. Метаболическая терапия L-карнитином при переднем остром инфаркте миокарда с подъемом сегмента ST: рандоминизированное клиническое исследование. Рос. кардиол. журн. 2011; 4: 77–84.
31. Therrien G, Rose C, Butterworth J, Butterworth R. Protectiveeffect of L-carnitine in ammonia-precipitated encephalopathy in the portacaval shuntedrat. Hepatology 1997; 25: 551–6.
32. Virmani A, Gaetani F, Imam S et al. Theprotective role of L-carnitine against neurotoxicity evoked by drug of abuse, methamphetamine, could berelated tomitochondrial dysfunction. Ann N Y Acad Sci 2002; 965: 225–32.
Авторы
А.Л.Верткин
ГБОУ ВПО МГМСУ Минздравсоцразвития РФ
ГБОУ ВПО МГМСУ Минздравсоцразвития РФ
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.